Vision-Native Spine Surgical Navigation Robot — $6M Pre-Series A (Cadaver-Validated, Pre-FDA 510(k))

FoxEyes Robotics (Plano, TX; Delaware C-corp) is raising a $6.0M Pre-Series A to fund FDA readiness and first commercial placements of the F1 VSR — a vision-native spinal navigation robot. The F1 VSR uses computer vision plus robot kinematics to eliminate the markers, calibration steps, and line-of-sight constraints that make legacy spine robots (~$1.2M) costly and complex — targeting an ~$0.85M price point and a smaller footprint built for the mid-sized hospitals and ambulatory surgery centers (ASCs) that legacy systems can't reach. Traction to date: • First production article complete • Sub-millimeter navigation accuracy validated via ASTM F2554 testing and cadaver testing at Baylor Scott & White Hospital (100% Grade A on the Gertzbein-Robbins scale) • Class II 510(k) regulatory pathway with cleared predicates identified; submission targeted late 2026, FDA clearance expected Q1 2027 • Filed US and Korea patent portfolio around the core tracking architecture Business model: capital equipment sales (~$0.85M/unit) plus recurring service contracts (~$120K/yr/unit) and per-case disposables. Use of proceeds: regulatory and V&V, manufacturing readiness, commercial launch preparation, and team/operating capital through clearance. Market context: the spine-robotics category has a well-defined strategic-acquirer landscape — Medtronic/Mazor and Stryker/Mako were each roughly $1.6B acquisitions. Seeking: medtech/device investors, surgical-robotics and healthcare-focused funds, family offices, and strategic/corporate venture partners. Full investor package and data room available on request. Contact: Brandon McNally, CFO — redacted · ###-###-#### 4115v